Want to see SBFM full AI Analyst Report?
Sunshine Biopharma (SBFM) AI Stock Analysis
Sunshine Biopharma
(NASDAQ:SBFM)
SBFM scores at the low end of the range. The dominant drivers are weak fundamentals — persistent losses, a -41.3% TTM revenue decline, compressing gross margins, and chronic negative operating and free cash flow with no demonstrated path to breakeven. Technicals reinforce the concern, with the stock trading dramatically below all major moving averages and a deeply negative MACD; the oversold RSI is the only tentative positive. Dilutive financing, repriced warrants, and a potential reverse stock split under highly concentrated insider voting control add further shareholder risk. A debt-light balance sheet with $27.5M of equity is the main offsetting strength, but it is not enough to outweigh the cash burn and negative momentum.
Sunshine Biopharma (SBFM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.22M
- Dividend Yield
- ―
- Average Volume (3M)
- 299.56K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.75
- Revenue Growth
- -2.74%
- EPS Growth
- 60.85%
- Country
- US
- Employees
- 50
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Sunshine Biopharma Business Overview & Revenue Model
Company Description
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluo...
Sunshine Biopharma Financial Statement Overview
Summary
Financials are weak overall. The income statement (score 22) shows persistent net losses (-$5.8M TTM, -16.5% net margin), a sharp TTM revenue decline of -41.3%, and gross margins compressing from ~48% to ~30%. Cash flow (score 15) is the biggest concern, with chronically negative operating (-$5.3M) and free cash flow (-$4.6M) and no period of positive cash generation, implying ongoing reliance on external financing. The balance sheet (score 55) is the only relative strength, with $27.5M of equity, minimal debt ($678K) and a debt-to-equity of just 0.025, though ROE is deeply negative at -24.2%.
Income Statement
22NegativeBalance Sheet
55NeutralCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.35M | 36.31M | 34.87M | 24.09M | 4.35M | 228.43K |
| Gross Profit | 10.53M | 11.92M | 10.67M | 8.34M | 1.70M | 110.60K |
| EBITDA | -5.26M | -5.62M | -5.14M | -3.82M | -26.45M | -12.09M |
| Net Income | -5.83M | -5.98M | -5.13M | -4.51M | -26.74M | -12.44M |
Balance Sheet | ||||||
| Total Assets | 33.63M | 30.08M | 30.56M | 27.35M | 29.55M | 2.20M |
| Cash, Cash Equivalents and Short-Term Investments | 13.75M | 9.12M | 9.69M | 16.29M | 21.83M | 2.05M |
| Total Debt | 678.34K | 812.42K | 952.48K | 657.71K | 765.26K | 1.90M |
| Total Liabilities | 6.09M | 7.04M | 7.06M | 6.14M | 7.92M | 1.99M |
| Stockholders Equity | 27.54M | 23.04M | 23.50M | 21.21M | 21.63M | 211.66K |
Cash Flow | ||||||
| Free Cash Flow | -4.60M | -5.51M | -14.85M | -9.56M | -5.55M | -1.83M |
| Operating Cash Flow | -5.33M | -5.33M | -12.53M | -8.78M | -5.25M | -1.83M |
| Investing Cash Flow | -278.14K | -836.31K | -2.32M | -656.15K | -14.62M | 0 |
| Financing Cash Flow | 8.60M | 4.75M | 9.29M | 3.43M | 39.47M | 2.90M |
Sunshine Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 2.93 is below the 20-day moving average (MA) of 5.26, below the 50-day MA of 14.16, and below the 200-day MA of 109.05, indicating a bearish trend. The MACD of -3.39 indicates Negative momentum. The RSI at 27.31 is Positive, neither overbought nor oversold. The STOCH value of 22.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.
Sunshine Biopharma Risk Analysis
Sunshine Biopharma disclosed 32 risk factors in its most recent earnings report. Sunshine Biopharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskSunshine Biopharma Peers Comparison
Overall Rating
YCBD43Neutral
SNOA42Neutral
IMCC38Underperform- SBFM34Underperform
SHPH32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| YCBD | 43Neutral | $4.29M | -1.25 | -34.25% | ― | 10.01% | 95.01% |
| SNOA | 42Neutral | $5.27M | -0.90 | -53.56% | ― | 47.00% | 50.49% |
| IMCC | 38Underperform | $1.30M | -0.03 | 841.81% | ― | -11.91% | -285.26% |
| SBFM | 34Underperform | $2.23M | -0.01 | -24.23% | ― | -2.74% | 60.85% |
| SHPH | 32Underperform | $24.54M | -0.17 | -156.78% | ― | ― | 94.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SBFM | Sunshine Biopharma, Inc. | 2.93 | -339.07 | -99.14% | |
| SNOA | Sonoma Pharmaceuticals, Inc. | 1.10 | -2.68 | -70.90% | |
| YCBD | Cbdmd INc | 0.38 | -0.46 | -54.52% | |
| IMCC | Im Cannabis Corp | 0.79 | -40.91 | -98.10% | |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | 5.15 | -25.85 | -83.39% |
Sunshine Biopharma Corporate Events
Sunshine Biopharma Approves Dilutive Share Issuance Plan
NegativeOn October 13, 2026, Sunshine Biopharma’s CEO, Dr. Steve N. Slilaty, who controls about 90% of the company’s voting power, approved issuing more than 20% of the firm’s outstanding common shares at a discount to the Nasdaq minimum pr...
Sunshine Biopharma Completes $6 Million Public Offering
PositiveOn October 8, 2026, Sunshine Biopharma entered a placement agent agreement with Aegis Capital for a reasonable best efforts public offering of 10,509,082 common units and 400,000 pre‑funded units, each combining common stock or pre‑funded...
Sunshine Biopharma CEO Authorizes Potential Reverse Stock Split
NegativeOn September 15, 2026, Sunshine Biopharma’s majority voting shareholder and CEO, Dr. Steve N. Slilaty, approved a written consent authorizing the board to implement a reverse split of the company’s common stock at a ratio of up to 1-for-2...
Sunshine Biopharma Adjusts Series B Warrant Exercise Price
NegativeAs of the date of the filing referenced in the report, Sunshine Biopharma Inc. disclosed that recent sales of its common stock under a previously announced at-the-market offering triggered an adjustment to the exercise price of its outstanding Series...
Sunshine Biopharma Announces Upcoming Board Leadership Change
NeutralOn August 25, 2026, Sunshine Biopharma Inc. disclosed that director Dr. Andrew Keller notified the company he will not seek or accept reelection to its Board of Directors. His current term is set to expire at the company’s next annual sharehold...
Sunshine Biopharma Adjusts Series B Warrant Terms
NeutralAs of the latest report filing date, Sunshine Biopharma Inc. disclosed that recent sales of its common stock under a previously announced at-the-market offering triggered an adjustment to the terms of its outstanding Series B Warrants. The exercise p...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026